Clinical trials
Hematopoietic Stem Cell Transplant clinical trials
Below are recruiting hematopoietic stem cell transplant clinical trials, each written for real people, not researchers. We’re tracking 369 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07358195RecruitingEarly Phase 1
Combined stem cell and kidney transplant from a relative
This trial tests a combined transplant of blood-forming stem cells and a kidney from the same family member. It aims to help people with both advanced kidney failure and a blood cancer by potentially reducing the need for lifelong anti-rejection medicines.
Boston, MassachusettsAges 18–70 - NCT06845592Recruiting
Stronger radiation and cell therapy before stem cell transplant for high-risk leukemia
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
Perugia, PGAges 18–65 - NCT07349498Recruiting
Heart health after stem cell transplant
This study follows patients who have had a stem cell transplant to see how their heart and blood vessels are doing over time. It helps doctors learn about long-term heart risks after transplant.
Beijing, Beijing MunicipalityAges Any age - NCT07347990Recruiting
Iptacopan for high-risk TA-TMA after stem cell transplant
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
Hangzhou, ChinaAges 12 years+ - NCT07341698Recruiting
Prehabilitation before stem cell transplant for blood cancer
This trial tests a prehabilitation program for patients with blood cancer who are scheduled for an allogeneic stem cell transplant. The goal is to help improve your physical and emotional strength before the transplant.
Copenhagen, DenmarkAges 18 years+ - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT06792682RecruitingPhase 1
Cord blood cells for poor graft function after transplant
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07315165RecruitingPhase 2
Liquid nutrition vs. standard care after stem cell transplant
This trial tests whether giving liquid nutrition through a tube (enteral nutrition) can improve recovery after a stem cell transplant for a blood disorder, compared to standard care where patients eat normally or use other nutrition support.
Omaha, NebraskaAges 19 years+ - NCT07301866RecruitingPhase 1/Phase 2
Testing an improved dose of UM171 for cord blood transplant
This trial tests a higher dose of UM171 to make cord blood transplants safer and more effective for people with certain blood cancers or bone marrow diseases. It aims to help patients who don't have a suitable donor.
Montreal, QuebecAges 18–67 - NCT07297303Recruiting
Lung health study after stem cell transplant
This study follows lung health after a stem cell transplant from a donor, to understand and manage chronic graft-versus-host disease (a condition where donor cells attack the body). It may help people who are about to have their first donor transplant.
TaipeiAges 18 years+ - NCT03667599Recruiting
Home care program after your stem cell transplant
This study tests whether extra home-based medical support after a stem cell transplant can help patients during recovery. If you’re eligible, a trained care team will support you at home so you’re safer and better managed after discharge.
Durham, North CarolinaAges 18–80 - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT07284641RecruitingPhase 2
Stem cell transplant for immune disorders
This trial tests a stem cell transplant to treat common variable immunodeficiency (CVID) and other immune problems. It aims to replace a faulty immune system with a healthy one from a donor.
Pittsburgh, PennsylvaniaAges 5–40 - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT05855083RecruitingPhase 2
Narsoplimab for high-risk TMA after bone marrow transplant
This trial studies the medicine narsoplimab in children who develop a serious complication called HSCT-TMA after a bone marrow transplant. It aims to improve safety and effectiveness for high-risk cases where the condition is ongoing or causing organ problems.
San Diego, CaliforniaAges 4 weeks–17 years - NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07252050RecruitingPhase 1/Phase 2
Ruxolitinib and half-matched transplant for severe sickle cell disease
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Aurora, ColoradoAges 12–45 - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT07244419RecruitingEarly Phase 1
Preventing stem cell transplant rejection in children
This early-phase trial tests a medication to prevent rejection of donated stem cells in children. It's for patients who are at high risk for their transplant to fail.
Cincinnati, OhioAges Any age - NCT06089850Recruiting
Emotional effects of stem cell donation on haploidentical donors
This study looks at the emotional and psychological impact on people who donate stem cells to a family member (a haploidentical donor). It aims to understand how the donation experience affects donors.
ParisAges 18 years+
Hear when a new Hematopoietic Stem Cell Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematopoietic stem cell transplant?
- Yes. Clin2 currently lists 369 recruiting hematopoietic stem cell transplant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematopoietic stem cell transplant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematopoietic stem cell transplant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Stem Cell Transplant Complications
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplant
- Hematopoietic Cell Transplant
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.